-
DORA Trial: Chemotherapy-Free Maintenance in Platinum-Sensitive aTNBC
The Phase II DORA study, published in April 2024, evaluated the efficacy of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer (aTNBC).…
-
ASCO GU 2025 | Dr. Kan Gong & Dr. Eric Jonasch Discuss New Strategies and Future Perspectives in Kidney Cancer Treatment (Part II)
Clear cell renal cell carcinoma (ccRCC) is closely associated with dysregulation of the VHL pathway, leading to the overexpression of HIF-2α and activation of multiple oncogenic pathways. Targeting HIF-2α with therapies such as belzutifan has provided new hope for patients with VHL syndrome and even broader applications in kidney cancer treatment. At this year’s ASCO…
-
KEYNOTE-522: Pembrolizumab Improves Event-Free Survival in Early-Stage TNBC
The KEYNOTE-522 trial, published in May 2024, highlights how pembrolizumab combined with chemotherapy improves event-free survival (EFS) in early-stage triple-negative breast cancer (TNBC), particularly across Residual Cancer Burden (RCB) categories.…
-
The RIGHT Choice Trial: Ribociclib Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer
The RIGHT Choice trial, published in August 2024, evaluated the efficacy of ribociclib plus endocrine therapy (ET) versus combination chemotherapy (CT) as a first-line treatment in premenopausal women with clinically…
-
Rebecca Dent and the IMpassion132 Trial: Investigating Immunotherapy in Rapidly Relapsing TNBC
The IMpassion132 phase III trial, published in July 2024, explored the impact of atezolizumab combined with chemotherapy for patients with rapidly relapsing, unresectable locally advanced or metastatic triple-negative breast cancer…
-
Emerging Biomarkers in Combination Therapy: Advancing Immunotherapy Strategies for Lung Cancer
Immuno-oncology (IO) has revolutionized the treatment landscape for non-small cell lung cancer (NSCLC), providing durable responses and survival benefits across different disease stages. The success of immune checkpoint inhibitors (ICIs), including PD-(L)1 and CTLA-4 inhibitors, has paved the way for dual immune checkpoint blockade (ICB) therapy, aiming to enhance antitumor immunity. While clinical trials such…
-
Dr.Lise Gehrt Cardél has led a groundbreaking study that sheds new light on the broader health benefits of the measles-mumps-rubella (MMR) vaccine
Dr.Lise Gehrt Cardél has led a groundbreaking study that sheds new light on the broader health benefits of the measles-mumps-rubella (MMR) vaccine. This large-scale, nationwide cohort study across Denmark, Finland, Norway, and Sweden found that children who received MMR after the diphtheria-tetanus-acellular pertussis (DTaP) vaccine had lower rates of infectious disease hospitalizations, suggesting potential non-specific…
-
Dr. Petek Eylül Taneri, MD, PhD has led a landmark study published in JAMA Network Open
Dr. Petek Eylül Taneri, MD, PhD has led a landmark study published in JAMA Network Open, setting a new standard for neonatal sepsis research. The Neonatal Sepsis Core Outcome Set (NESCOS) is a global consensus that defines the key outcomes to be measured in all future studies on neonatal sepsis, ensuring consistency, comparability, and impact.
Connecting Medical Expertise through Media